A furore too far: the widespread disquiet undermining NICE.
Carlisle
Daloni
D
D000047:Academies and Institutes / Q000458:organization & administration*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001943:Breast Neoplasms / Q000188:drug therapy; D003362:Cost-Benefit Analysis; D003659:Decision Making, Organizational; D017277:Drug Approval; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D017410:Practice Guidelines as Topic; D011320:Primary Health Care / Q000592:standards*; D013673:Technology Assessment, Biomedical / Q000379:methods / Q000458:organization & administration*; D000068878:Trastuzumab; D006113:United Kingdom
D000806:Angiotensin-Converting Enzyme Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068878:Trastuzumab